翰森制药集团有限公司（03692）于2026年3月2日发布截至2026年2月28日的证券变动月报表。报告显示，公司在本报告期内注册股本及已发行股本维持稳定，无新增发行、购回或库存股变动活动。
报告披露，公司法定或注册股本维持在20,000,000,000股，面值为每股0.00001港元，总额20万港元。截至2月底，已发行普通股股份总数依旧为6,055,150,070股，库存股份为零，无任何增减变动。
月报同时显示，公司于2026年2月3日发行了于2033年到期的零息可换股债券，规模为港币46.80亿元，转股价为每股57.39港元，若全部转股或转让，最多可新增81,547,308股。截至报告期末，尚未有因该可换股债券实际转换而带来的股本变动。
公告确认公司现时已符合香港联交所对于最低公众持股量16.21%的相关要求。月报由联席公司秘书钟胜利女士签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.